17.09.2019, 13:32
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
https://finance.yahoo.com/news/aclaris-t...jlBzxUKwPj
Aktuell vorbörslich: $1.81 +65%
Übernachthoch: $2.32
![[Bild: chart.ashx?t=ACRS&ty=c&ta=1&p=d&s=l]](https://www.finviz.com/chart.ashx?t=ACRS&ty=c&ta=1&p=d&s=l)
- Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29
- Highly statistically significant results on all secondary efficacy endpoints
- WART-302 is the first of two Phase 3 pivotal trials for the NDA
- If approved, A-101 45% Topical Solution would be the first FDA approved prescription treatment for common warts
https://finance.yahoo.com/news/aclaris-t...jlBzxUKwPj
Aktuell vorbörslich: $1.81 +65%
Übernachthoch: $2.32